Phase 1 Study of In Utero Enzyme Replacement Therapy for the Treatment of Lysosomal Storage Diseases
子宫内酶替代疗法治疗溶酶体贮积病的一期研究
基本信息
- 批准号:10707992
- 负责人:
- 金额:$ 66.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-20 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectAntibodiesAntibody TherapyAttitudeBackBiochemicalBirthBloodBlood TransfusionBrainCardiacCardiomyopathiesChildClinical TrialsCollaborationsDataDevelopmentDiagnosisDiseaseEdemaEducationEnrollmentEnsureEnzyme InductionEnzymesExposure toFDA approvedFamilyFetal safetyFetusFunctional disorderFundingFutureGenerationsGeneticGenotypeGlycogen storage disease type IIGlycosaminoglycansGoalsGrowthHydrops FetalisImmuneImmune responseIncidenceIndividualInfrastructureInfusion proceduresInjectionsInternationalInvestigational DrugsLive BirthLysosomal Storage DiseasesMeasuresMedicalMicrogliaMucopolysaccharidosesMucopolysaccharidosis VIIMusMutationNervous System PhysiologyNervous System TraumaNeurocognitive DeficitNeurologic EffectNew Drug ApprovalsOrganOutcomeParentsPathologyPatient ParticipationPatientsPenetrationPerinatalPerinatal mortality demographicsPharmaceutical PreparationsPhase I Clinical TrialsPhenotypePregnancyPregnant WomenProgressive DiseaseProteinsProtocols documentationPublishingRecombinantsRecording of previous eventsRegulatory T-LymphocyteRespondentRiskSafetySeveritiesSiblingsSiteSurveysTechniquesTestingTimeUmbilical veinWolman Diseaseblood-brain barrier crossingblood-brain barrier penetrationdesigndisease prognosiseffective therapyenzyme replacement therapyexome sequencingexperiencefetalfirst-in-humangenetic testingheart functionimmunoreactionimprovedimproved outcomein uteroinfancymaternal safetymouse modelmultidisciplinarymultiorgan damageorgan growthpatient advocacy grouppediatric patientsperinatal morbiditypharmacokinetics and pharmacodynamicsphase 1 studypostnatalprenatalprenatal exposureprenatal therapypreventprogramssafety and feasibilityskeletal dysplasiaspecific biomarkerssuccesstreatment centertrial designultrasound
项目摘要
Lysosomal storage disorders (LSDs) are severe diseases arising from mutations in critical enzymes and
collectively have an estimated incidence of 1 in 5,000 to 1 in 5,500 live births. Patients with LSDs are at
increased risk of serious perinatal morbidity and mortality, with some not even surviving to birth. The current
treatment for pediatric patients, enzyme replacement therapy (ERT), is limited by three aspects: the
progressive development (sometimes in utero) of organ-specific manifestations, the development of anti-ERT
antibodies, and the inability of ERT to cross the blood-brain barrier to address neurologic effects. Thus, there is
an unmet medical need to develop more effective therapies for patients with LSDs, starting before birth. In a
mouse model of mucopolysaccharidosis type 7 (MPS7), we showed that in utero ERT (IUERT) followed by
postnatal ERT improved survival, crossed the blood-brain barrier, ameliorated disease, and induced tolerance
to the ERT. Based on these results, we obtained an IND to perform a first-in-human, non-randomized, single
site phase 1 clinical trial of IUERT and seek funding to support this clinical trial. Since each individual LSD is
rare, but they share similar pathophysiology, we have included eight different LSDs (and their specific ERT)
under this protocol: MPS Types 1, 2, 4a, 6, and 7, Infantile-onset Pompe Disease (IOPD), Neuronopathic
Gaucher (Types 2 and 3), and Wolman disease. We will enroll 10 maternal-fetal pairs for infusion of the ERT
via the umbilical vein every 2-4 weeks, starting after 18 weeks of gestation. We will evaluate the safety and
feasibility of this prenatal therapy, as well as the efficacy of ERTs in resolving fetal manifestations (if present)
and improving long-term outcomes including neurologic and cardiac function, mobility, and growth. (Aim 1). We
will also examine the pharmacokinetics and pharmacodynamics of IUERT by evaluating enzyme trough levels
throughout gestation, as well as levels of disease-specific lysosomal accumulations before and after birth (Aim
2). Finally, we will evaluate whether in utero exposure to the recombinant enzyme will induce tolerance, as
determined by lack of anti-drug antibodies and generation of enzyme-specific regulatory T cells (Aims 3). In the
past year, our team has successfully treated a fetus with IOPD (whose two previous siblings had severe
cardiomyopathy and suffered perinatal demise); this patient was born at term after multiple prenatal enzyme
infusions and has normal cardiac function. We have assembled a multidisciplinary team and partnered with
several experts on biochemical analyses for LSDs. Since we anticipate identifying fetuses based on a known
family history, we have also been collaborating with multiple national and international patient advocacy groups
to include patients and families in the design and execution of this trial. We conducted a parent survey to
evaluate their attitudes and found that the majority of respondents would choose to enroll in a phase I clinical
trial for fetal ERT for a future pregnancy affected by an LSD. Ultimately, we seek to improve the options
available to families and patients with LSDs.
溶酶体储存障碍(LSD)是一种严重的疾病,由关键酶和
总体而言,估计发病率为每5000人中有1人到每5500名活产儿中有1人。患有LSD的患者在
增加严重围产期发病率和死亡率的风险,有些人甚至活不到出生。海流
儿科患者的治疗,即酶替代疗法(ERT),受到三个方面的限制:
器官特异性表现的进行性发展(有时在子宫内),抗ERT的发展
抗体,以及ERT无法跨越血脑屏障来解决神经影响。因此,有
一个尚未得到满足的医疗需求是为LSD患者开发更有效的治疗方法,从出生前开始。在一个
7型粘多糖病(MPS7)的小鼠模型,我们发现子宫内ERT(IUERT)其次是
出生后ERT可提高存活率,跨越血脑屏障,改善疾病,并诱导耐受
送到急诊室。基于这些结果,我们获得了一种IND,以执行人类第一次、非随机、单
IUERT的现场1期临床试验,并寻求资金支持这项临床试验。因为每个单独的LSD
罕见,但它们具有相似的病理生理,我们包括了八种不同的LSD(及其特定的ERT)
根据该方案:MPS 1、2、4a、6和7型,婴儿起病庞贝病(IOPD),神经病理性
Gaucher(2型和3型)和Wolman病。我们将招募10对母婴进行ERT输液
妊娠18周后开始,每2-4周经脐静脉注射一次。我们将评估其安全性和
这种产前治疗的可行性,以及ERTS在解决胎儿表现方面的效果(如果存在)
并改善长期结果,包括神经和心脏功能、活动能力和生长发育。(目标1)。我们
我还将通过评估酶水平来检查IUERT的药代动力学和药效学
在整个妊娠期间,以及出生前和出生后特定于疾病的溶酶体积聚水平(目的
2)。最后,我们将评估在子宫内暴露于重组酶是否会诱导耐受,如
由缺乏抗药物抗体和产生酶特异性调节T细胞决定(AIMS 3)。在
在过去的一年里,我们团队成功地治疗了一名患有IOPD的胎儿(他的前两个兄弟姐妹患有严重的
心肌病和围产期死亡);这名患者是在多种产前酵素过后足月出生的
输液,心脏功能正常。我们已经组建了一个多学科团队,并与
几位LSD生化分析方面的专家。因为我们预计会根据已知的
家族病史,我们也一直在与多个国家和国际患者权益倡导团体合作
让患者和家属参与这项试验的设计和执行。我们进行了一项家长调查,以
评估他们的态度,发现大多数受访者会选择注册I期临床
对受LSD影响的未来妊娠进行胎儿ERT的试验。最终,我们寻求改善各种选择
适用于患有LSD的家庭和患者。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tippi Mackenzie其他文献
Tippi Mackenzie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tippi Mackenzie', 18)}}的其他基金
Developing gene therapy strategies to treat alpha thalassemia
开发治疗α地中海贫血的基因治疗策略
- 批准号:
10345618 - 财政年份:2022
- 资助金额:
$ 66.63万 - 项目类别:
Developing gene therapy strategies to treat alpha thalassemia
开发治疗α地中海贫血的基因治疗策略
- 批准号:
10545021 - 财政年份:2022
- 资助金额:
$ 66.63万 - 项目类别:
Phase 1 Study of In Utero Enzyme Replacement Therapy for the Treatment of Lysosomal Storage Diseases
子宫内酶替代疗法治疗溶酶体贮积病的一期研究
- 批准号:
10542951 - 财政年份:2022
- 资助金额:
$ 66.63万 - 项目类别:
Autoimmune Regulator gene (Aire)-mediated tolerance to pregnancy-associated self-antigens
自身免疫调节基因(Aire)介导的对妊娠相关自身抗原的耐受性
- 批准号:
10219063 - 财政年份:2019
- 资助金额:
$ 66.63万 - 项目类别:
Autoimmune Regulator gene (Aire)-mediated tolerance to pregnancy-associated self-antigens
自身免疫调节基因(Aire)介导的对妊娠相关自身抗原的耐受性
- 批准号:
10455466 - 财政年份:2019
- 资助金额:
$ 66.63万 - 项目类别:
Autoimmune Regulator gene (Aire)-mediated tolerance to pregnancy-associated self-antigens
自身免疫调节基因(Aire)介导的对妊娠相关自身抗原的耐受性
- 批准号:
10684826 - 财政年份:2019
- 资助金额:
$ 66.63万 - 项目类别:
T cell activation and the breakdown of maternal-fetal tolerance in preterm labor
早产中 T 细胞激活和母胎耐受性崩溃
- 批准号:
9079351 - 财政年份:2015
- 资助金额:
$ 66.63万 - 项目类别:
T cell activation and the breakdown of maternal-fetal tolerance in preterm labor
早产中 T 细胞激活和母胎耐受性崩溃
- 批准号:
9280814 - 财政年份:2015
- 资助金额:
$ 66.63万 - 项目类别:
Maternal and fetal immune responses to in utero HSC transplantation
母体和胎儿对宫内 HSC 移植的免疫反应
- 批准号:
8465803 - 财政年份:2010
- 资助金额:
$ 66.63万 - 项目类别:
Maternal and fetal immune responses to in utero HSC transplantation
母体和胎儿对宫内 HSC 移植的免疫反应
- 批准号:
7771488 - 财政年份:2010
- 资助金额:
$ 66.63万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 66.63万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 66.63万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 66.63万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 66.63万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 66.63万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 66.63万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 66.63万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 66.63万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 66.63万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 66.63万 - 项目类别:
Grant-in-Aid for Early-Career Scientists